Profitable failure: Antidepressant drugs and the triumph of flawed experiments

History of the Human Sciences

Volumn 23, Issue 1, 2010, Pages 58-78

  McGoey, Linsey ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ambiguity; Antidepressants; Clinical trials; Strategic ignorance; Valuable failure

Indexed keywords

ANTIDEPRESSANT AGENT; DRUG;

ARTICLE; CLINICAL TRIAL; ECONOMICS; HISTORY; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIAL; TECHNIQUE; TREATMENT FAILURE;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; ECONOMICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; METHODS; OBSERVER VARIATION; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 77649280989     PISSN: 09526951     EISSN: 1461720X     Source Type: Journal    
DOI: 10.1177/0952695109352414     Document Type: Article

References (49)

1. Abraham, J. (2007) Drug Trials in International Regulatory Context, Biosocieties 2: 41-56.
2. Abraham, J. and Sheppard, J. (1999) Complacent and Conflicting Scientific Expertise in British and American Drug Regulation: Clinical Risk Assessment of Triazolam, Social Studies of Science 29: 803-43.
3. Barry, A. (2006) Technological Zones, European Journal of Social Theory 9: 239-53.
4. Bourdieu, P. (1992) The Logic of Practice. Stanford, CA: Stanford University Press.
5. Bourdieu, P. (1999) Rethinking the State: Genesis and Structure of the Bureaucratic Field, in State/Culture: State Formation after the Cultural Turn, ed. G. Steinmetz. Ithaca, NY: Cornell University Press, pp. 53-75.
6. Chalmers, I. (2005) Statistical Theory was not the Reason that Randomization was used in the British Medical Research Council's Clinical Trial of Streptomycin for Pulmonary Tuberculosis, in G. Jorland, A. Opinel and G. Weisz (eds) Body Counts: Medical Quantification in Historical and Sociological Perspective. Montreal and Kingston: McGill-Queen's University Press.
7. Corrigan, O.P. (2002) A Risky Business: the Detection of Adverse Drug Reactions in Clinical Trials and Post-Marketing Exercises, Social Science & Medicine 55: 497-507.
8. Daston, L. (1994) 'Baconian Facts, Academic Civility, and the Prehistory of Objectivity', in Rethinking Objectivity, ed. A. Megill. Durham, NC: Duke Univerrsity Press.
9. Daston, L. and Sibum, O.H. (2003) Introduction: Scientific Personae and Their Histories, Science in Context 16: 1-8.
10. Dehue, T. (2002) A Dutch Treat: Randomized Controlled Experimentation and the Case of Heroin-Maintenance in the Netherlands, History of the Human Sciences 15: 75-98.
11. Doll, R. (2003) Fisher and Bradford Hill: Their Personal Impact, International Journal of Epidemiology 32: 929-31.
12. Graham, J. (2008) Facilitating Regulation: The Dance of Statistical Significance and the Clinical Meaningfulness in Standardizing Technologies for Dementia, BioSocieties 3: 241-63.
13. Healy, D. (2001) The Dilemma posed by New and Fashionable Treatments, Advances in Psychiatric Treatment 7: 322-7.
14. Healy, D. (2006) The Antidepressant Tale: Figures signifying Nothing?, Advances in Psychiatric Treatment 12: 320-7.
15. Healy, D. (2009) Trussed in Evidence? Ambiguities at the Interface between Clinical Evidence and Clinical Practice, Transcultural Psychiatry 46: 16-37.
16. Heimer, C.A., Petty Coleman, J. and Culyba, R.J. (2005) Risk and Rules: the Legalization of Medicine, in B. Hutter and M. Power (eds) Organizational Encounters with Risk. Cambridge: Cambridge University Press.
17. Huberty, C.J. (2002) A History of Effect Size Indices, Educational and Psychological Measurement 22: 227-40.
18. Kaptchuk, T. (1998) Intentional Ignorance: a History of Blind Assessment and Placebo Controls in Medicine, Bulletin of the History of Medicine 72(3): 389-433.
19. Kendall, T. and McGoey, L. (2007) Truth, Disclosure, and the Influence of Industry on the Development of NICE Guidelines: an Interview with Tim Kendall, BioSocieties 2: 129-41.
20. Kirsch, I., Deacon, B., Heudo-Medina, T., Scoboria, A., Moore, T. and Johnson, B. (2008) Initial Severity and Antidepressant Benefits: a Meta-Analysis of Data submitted to the Food and Drug Administration, PLos Medicine 5: e45. doi: 10.1371/journal.pmed.0050045.
21. Lakoff, A. (2005) Pharmaceutical Reason: Knowledge and Value in Global Psychiatry. Cambridge: Cambridge University Press.
22. Lakoff, A. (2007) The Right Patients for the Drug: Managing the Placebo Effect, Biosocieties 2: 57-73.
23. Lamble, S. (2009) 'Unknowable Bodies, Unthinkable Sexualities: Lesbian and Trans-gender Legal Invisibility in the Toronto Women's Bathhouse Raid', Social & Legal Studies 18: 111-30.
24. Latour, B. (1986) Visualization and Cognition: Thinking with Eyes and Hands, Knowledge and Society 6: 1-40.
25. Lezaun, J. (2007) A Market of Opinions: the Political Epistemology of Focus Groups, The Sociological Review 55(2): 130-51.
26. Marks, H.M. (1997) The Progress of Experiment. Cambridge: Cambridge University Press.
27. McGoey, L. (2007) On the Will to Ignorance in Bureaucracy, Economy and Society 36: 212-35.
28. McGoey, L. (2009) Resistance Scripts: the Authority of Method within Regimes of Evidence, in C. Calhoun and R. Sennett (eds) Creating Authority. London: Routledge.
29. Miller, F.G. and Brody, H. (2002) What makes Placebo-Controlled Trials Unethical?, American Journal of Bioethics 2: 3-9.
30. Miller, F.G. and Silverman, H.J. (2004) The Ethical Relevance of the Standard of Care in the Design of Clinical Trials, American Journal of Respiratory and Critical Care Medicine 169: 562-4.
31. Moncrieff, J. (2002) The Antidepressant Debate, British Journal of Psychiatry 180: 193-4.
32. Moncrieff, J. and Kirsch, I. (2005) Efficacy of Antidepressants in Adults, British Medical Journal 331: 155-7.
33. Nice (2004) Depression: Management of Depression in Primary and Secondary Care, National Clinical Practice Guideline Number 23: online (last accessed March 2008) at: http://www.nice.org.uk/nicemedia/pdf/cg023fullguideline.pdf.
34. Petryna, A. (2007) Clinical Trials Offshored: On Private Sector Science and Public Health, BioSocieties 2: 21-41.
35. Porter, T. (1995) Trust in Numbers: The Pursuit of Objectivity in Science and Public Life. Princeton, NJ: Princeton University Press.
36. Power, M. (1994) The Audit Explosion. London: White Dove Press.
37. Proctor, R. (1995) Cancer Wars: How Politics Shapes What We Know and Don't Know about Cancer. New York: HarperCollins.
38. Rose, N. (1999) Powers of Freedom: Reframing Political Thought. Cambridge: Cambridge University Press.
39. Sunder Rajan, K. (2007) Experimental Values: Indian Clinical Trials and Surplus Health, New Left Review 45: 67-88.
40. Taussig, M. (1999) Defacement: Public Secrecy and the Labor of the Negative. Stanford, CA: Stanford University Press.
41. Timmermans, S. (2005) From Autonomy to Accountability: the Role of Clinical Practice Guidelines in Professional Power, Perspectives in Biology and Medicine 48: 490-501.
42. Timmermans, S. and Berg, M. (2003) The Gold Standard: The Challenge of Evidence-Based Medicine and Standardization in Health Care. Philadelphia, PA: Temple University Press.
43. Turner, E. and Rosenthal, R. (2008) Efficacy of Antidepressants is not an Absolute Measure, and it depends on How Clinical Significance is defined, British Medical Journal 336: 516-17.
44. Vrecko, S. (2008) Capital Ventures in Biology: Biosocial Dynamics in the Industry and Science of Gambling, Economy and Society 37: 50-67.
45. Wahlberg, A. (2008) Above and Beyond Superstition - Western Herbal Medicine and the Decriminalising of Placebo, History of the Human Sciences 21: 77-101.
46. Wahlberg, A. and McGoey, L. (2007) An Elusive Evidence Base: the Construction and Governance of Randomised Controlled Trials (Introduction to Special Issue), BioSocieties 2: 1-11.
47. Will, C. (2007) The Alchemy of Clinical Trials, Biosocieties 2: 85-101.
48. Wilson, E. (2008) Ingesting Placebo, Australian Feminist Studies 23: 31-42.
49. Ziliak, S. and McCloskey, D. (2008) The Cult of Statistical Significance: How the Standard Error Costs Us Jobs, Justice and Lives. Ann Arbor: University of Michigan Press.